skip to content

Axis 2: Group discussions and plenary session

This chapter presents the key items emerging from the working group discussions and the plenary session.
They are classified by day and particular subject (by working group):

  • For each day, we have first recorded the questions which were posed for further thought.
  • For each subject (working group), we present, in the form of a slide show: (i) The key ideas exchanged in the group, as reported to the plenary session, (ii) A summary of the discussion and the most significant commentaries emerging from the final debate in plenary session.

Questions for further reflection

What potential initiatives can be realistically taken to improve the quality and effectiveness of the supply chain:

1. At the level of financial mechanisms for improving access to MEGs
  • How can the market in medicines in the context of applying new health financing mechanisms be developed (PBF, medical insurance,..)
  • Extension of basic principles of AMFm and A2S2 projects to other types of product?
2. At the level of organization of public supply networks:
  • What coordination strategy is needed at the level of technical and financial partners and executive agents for dealing with the multiplication of parallel supply circuits?
  • What room for manoeuvre is there for public purchasing authorities in financing their needs?
  • Can a public purchasing authority generate a profit? How can this profit be put to use in ways that do not contradict its humanitarian mission?
  • What does the future hold for public purchasing authorities? What strategic and commercial options are available for anticipating probable developments in the sector
3. At the private sector level: what complementarity is there with the public sector and what forms of public private sector partnership are possible?
  • Can States Function with no system of public procurement, whilst at the same time regulating the market? How? Support measures required?
  • How can « social » goals in the private sector be compatible in the long term with a public health mission?
  • In a completely private system, how can non profit supply of medicines be assured?